Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 3

2(28.6%)

Phase 1

2(28.6%)

7Total

Phase 2(3)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06717152Phase 3Completed

Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease

Role: collaborator

NCT04139122Phase 1Completed

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

Role: lead

NCT05320861Phase 1Completed

Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects

Role: lead

NCT03869684Phase 2Terminated

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

Role: lead

NCT02929823Phase 2Completed

Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

Role: lead

NCT02104388Phase 2Completed

Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

Role: lead

NCT03527212Phase 3Completed

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

Role: lead

All 7 trials loaded